2013-2018年全球口服霍乱疫苗使用情况
该研究回顾了WHO口服霍乱疫苗(OCV)储备库2013年7月至2018年全年的使用情况,分析了24个国家申请的83,509,941剂疫苗中获批55,409,160剂、最终在22个国家83次部署中发货36,066,010剂并开展104次接种活动。OCV总体接受度高(首剂行政覆盖90.3%、第二剂88.2%,调查估计两剂覆盖69.9%),未报告严重不良事件,但紧急情况下从事件发生到申请疫苗的中位延迟为26天。
要点
- OCV储备库是重要公共卫生资源,疫苗安全可行且成本较低(每剂2.98美元)。
- 接种活动组织迅速(中位持续时间5天),但紧急情况下申请延迟中位26天限制及时性。
- 监测评估改善形成良性循环,促进疫苗使用增加,仍需改进响应及时性。
核心结论
- OCV储备库是重要公共卫生资源,疫苗总体接受度高、安全可行且成本低廉,但紧急使用时及时性是限制因素。
主要发现
- 2013-2018年24个国家申请83,509,941剂OCV,获批55,409,160剂,最终在22个国家83次部署中发货36,066,010剂,开展104次接种活动。
- 首剂行政覆盖均值90.3%,第二剂88.2%,调查估计两剂覆盖69.9%,至少一剂84.6%,未报告严重不良事件。
- 接种活动中位持续时间5天,紧急情况下从事件发生到申请OCV的中位延迟为26天。
- 每剂疫苗接种平均成本2.98美元。
临床怎么用
- 在霍乱防控中可将OCV作为与水、环境卫生和个人卫生措施结合的關鍵干预,利用储备库快速组织接种活动。
- 紧急情况下需关注从事件发生到申请疫苗的延迟,改进响应及时性。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is a key intervention to prevent and control cholera in conjunction with water, sanitation and hygiene activities. An oral cholera vaccine (OCV) stockpile was established by the World Health Organization (WHO) in 2013. We reviewed its use from July 2013 to all of 2018 in order to assess its role in cholera control. We computed information related to OCV deployments and campaigns conducted including setting, target population, timelines, delivery strategy, reported adverse events, coverage achieved, and costs. In 2013-2018, a total of 83,509,941 OCV doses have been requested by 24 countries, of which 55,409,160 were approved and 36,066,010 eventually shipped in 83 deployments, resulting in 104 vaccination campaigns in 22 countries. OCVs had in general high uptake (mean administrative coverage 1st dose campaign at 90.3%; 2nd dose campaign at 88.2%; mean survey-estimated two-dose coverage at 69.9%, at least one dose at 84.6%) No serious adverse events were reported. Campaigns were organized quickly (five days median duration). In emergency settings, the longest delay was from the occurrence of the emergency to requesting OCV (median: 26 days). The mean cost of administering one dose of vaccine was 2.98 USD. The OCV stockpile is an important public health resource. OCVs were generally well accepted by the population and their use demonstrated to be safe and feasible in all settings. OCV was an inexpensive intervention, although timing was a limiting factor for emergency use. The dynamic created by the establishment of the OCV stockpile has played a role in the increased use of the vaccine by setting in motion a virtuous cycle by which better monitoring and evaluation leads to better campaign organization, better cholera control, and more requests being generated. Further work is needed to improve timeliness of response and contextualize strategies for OCV delivery in the various settings.
引用
- Pezzoli L. Global oral cholera vaccine use, 2013-2018. Vaccine. 2019. PMID: 31519444. doi:10.1016/j.vaccine.2019.08.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。